The mean bone pyrophosphate was 0.360 +/-0.15 mg/g in 8 controls and 1.22 +/-1.39 mg/g bone in 27 uremic patients (P less than 0.0025). 13 of the 27 uremic patients had bone pyrophosphate levels greater than 2 SD above control values. The ash content of uremic bones with increased pyrophosphate levels (group II) was 56 +/-9% as compared to 64 +/-2% in control bones (P less than 0.01) and 60 +/-7% in uremic bones having normal pyrophosphate levels (P less than 0.1) (group I). The magnesium content of bones in group II was 338 +/-47 as compared to 211 +/-13 (P less than 0.0005) in the controls and 294 +/-73 mmol/kg ash (P less than 0.05) in group I. In group II, but not group I, there was a significant inverse correlation between duration of dialysis and percent bone ash (r = -0.59) (P less than 0.05). A definite relationship existed between elevated bone pyrophosphate levels and soft tissue calcification. In group II the mean pulmonary calcium content was 530 +/-459 as compared to 32 +/-26 mmol/kg/ash in group I (P less than 0.0025). All patients with a bone pyrophosphate level greater than 1.4 mg/g bone had extensive pulmonary calcification. It is concluded that the excess bone pyrophosphate present in […] The ash content of uremic bones with increased pyrophosphate levels (group II) was 56±9% as compared to 64+2% in control bones (P < 0.01) and 60±7% in uremic bones having normal pyrophosphate levels (P < 0.1) (group I). The magnesium content of bones in group II was 338±47 as compared to 211±+13 (P < 0.0005) in the controls and 294+73 mmol/kg ash (P < 0.05) in group I. In group II, but not group I, there was a significant inverse correlation between duration of dialysis and percent bone ash (r = -0.59) (P < 0.05).
±0.15 mg/g in 8 controls and 1.22±1.39 mg/g bone in 27 uremic patients (P < 0.0025). 13 of the 27 uremic patients had bone pyrophosphate levels greater than 2 SD above control values.
The ash content of uremic bones with increased pyrophosphate levels (group II) was 56±9% as compared to 64+2% in control bones (P < 0.01) and 60±7% in uremic bones having normal pyrophosphate levels (P < 0.1) (group I). The magnesium content of bones in group II was 338±47 as compared to 211±+13 (P < 0.0005) in the controls and 294+73 mmol/kg ash (P < 0.05) in group I. In group II, but not group I, there was a significant inverse correlation between duration of dialysis and percent bone ash (r = -0.59) (P < 0.05).
A definite relationship existed between elevated bone pyrophosphate levels and soft tissue calcification. In group II the mean pulmonary calcium content was 530+ 459 as compared to 32±26 mmol/kg/ash in group I (P < 0.0025). All patients with a bone pyrophosphate level greater than 1.4 mg/g bone had extensive pulmonary calcification.
It is concluded that the excess bone pyrophosphate present in some uremic patients is either deposited in the apatite crystal in the transphosphorylated form or else as the magnesium salt since the pyrophosphate is resistant to pyrophosphatase and surface adsorption of pyrophosphate is not altered by the increased bone pyrophosphate levels. The excess bone pyrophosphate could disturb bone calcification mechanisms in uremic patients. The association between increased bone pyrophosphate and soft tissue calcification suggests that the disordered pyrophosphate metabolism may be important in the pathogenesis of extraosseous calcification.
INTRODUCTION
There are a number of reasons to think that a crystal inhibitor or stabilizer such as pyrophosphate (P207)1 may be important in altering the calcification mechanisms in uremic patients. Since the urine normally contains a number of substances including P207 which inhibit the precipitation of calcium and phosphate from solution (1) , it is expected that some of these compounds are retained by patients with severely compromised renal function. Somewhat in support of this view is the study of Yendt et al. (2) which showed that substances present in the sera of uremic patients inhibited the in vitro calcification of rachitic rat cartilage. More direct evidence that P207 metabolism is altered in dialyzed uremic patients is the finding of high P207 levels in visceral calcium-phosphate deposits in these patients (3) . In addition, elevated plasma and serum P207 levels have been reported in some uremic patients by Russell et Inorganic pyrophosphatase with a specific activity of 647 U/mg protein was obtained from Sigma Chemical Co., St. Louis, Mo., and had a reported activity of 1 U capable of liberating 1.0 /mol of inorganic othophosphate per min at pH 7.2 at 25°C. In all studies, 3 U of pyrophosphatase was used in a solution containing Tris buffer (pH 72) 25 mM NaCl, and 1 mM MgC12. Activity of the enzyme was verified by using a Na4P207 standard.
To determine if storage of frozen bone affected the P.O7 content, six bones were analyzed before and after 6 mo of freezing. The mean P207 content in the six bones before freezing was 0.59 and after freezing 0.67 mg/g bone (P > 0.20).
To exclude the possibility that hydrolysis of P2O7 occurred during the EDTA extraction, P2O7 measurements were performed on paired samples extracted for 2 and 24 h at 40C and room temperature. P207 measurements were similar in all samples. All P2O7 results are expressed as milligrams of Po1 p.
Statistical comparisons were carried using the t test. All results are given as mean-1 SD.
RESULTS
Bone pyrophosphate. The mean bone content in 8 control bones was 0.360±0.150 and in 27 uremic bones was 1.22±1.39 mg/g dry bone (P < 0.0025). The bone P207 levels in 13 of the 27 uremic patients were greater than 2 SD above control values.
To determine if the bone P207 was resistant to the action of inorganic pyrophosphatase, 25 mg of finely ground bone powder from controls and uremic patients was incubated with 3 U of inorganic pyrophosphatase for 2 h in a solution containing Tris buffer (pH 7.2) and magnesium. Synthetic apatite crystals (verified by X-ray diffraction analysis to have a crystal size similar to bone) previously equilibrated with P207, so that its P207 content was similar to that found in bone, was also incubated in the pyrophosphatase solution. Although the pyrophosphatase destroyed over 94% of sodium P207 and decreased the P2O7 adsorbed on synthetic apatite by over 40% it produced no consistent change in the P207 content of uremic and control bones (Table I) .
25-mg samples of control and uremic bones containing normal and elevated P207 levels were incubated in 2 ml of a solution containing 36 Ag/ml (P) P207 for 1 h to measure P207 adsorption by the bone crystals. The results expressed on an ash weight basis are shown in Table II. P207 uptake was similar in all bones irrespective of the initial P207 content. Synthetic apatite crystals took up slightly less P.O7 than the bone crystals (Table   II) .
To exclude the possibility that an increased amount of noncalcified bone matrix was responsible for the high P2O7 levels found in some uremic bones, P207 was mea- 2.0 2.1 Density FIGURE 1 Correlation between bone density and percent ash. Bones were obtained from controls, and uremic patients with normal, osteomalacic, and fibrotic bone disease. sured in bones obtained from three patients who had osteomalacia of nonuremic causes (Table III) . In all of these patients bone P207 was within the normal range.
Additional inorganic constituents of bone. Bones from the uremic patients were subdivided into two groups. Group I had bone P207 levels within the normal range and group II had bone P207 levels greater than 2 SD above normal (Table IV) . In both uremic groups, the bone calcium was significantly lower (P <0.025) and magnesium significantly higher (P <0.0025) than the controls. Group I patients had a slightly lower bone phosphorus than the controls and group II patients had significantly lower bone ash content than the controls (P < 0.01). In comparing the two uremic groups group II patients had significantly higher bone magnesium content (P < 0.05) and somewhat lower bone ash content than group I patients. Bone phosphorus was also slightly higher in group II patients (Table IV) .
Bone density was measured in 16 bones and found to correlate with bone ash content (r = 0.67) (P < 0.01) (Fig. 1) . Low percent ash, and in turn, reduced bone density was found in osteomalacic as well as fibrotic bones and could not be used to separate the type of bone disease. Since it was easier and more reproducible to measure bone ash than density the former determination was used for comparative purposes in this study. In the high bone P207 group (group II) there was a significant negative correlation between duration of dialysis and percent bone ash (r = -0.59) (P < 0.05) (Fig. 2) . Such a correlation was not found in group I (r = -0.43) (P < 0.1). No correlation was found between duration of dialysis and bone P207 content (r = 0.16) (P < 0.1) (Fig. 3) .
Correlation between bone Ps07 and soft tissue calcification. Heart and/or lung calcium content was measured in 8 control subjects, 10 patients in group I and II patients in group II. The cardiac and pulmonary calcium content was significantly higher in uremic patients having high bone P207 levels (group II) when compared to controls (P < 0.0025) and group I (P < 0.0025). In all patients with bone P207 above 1.4 mg/g there was extensive pulmonary calcification (Table V) . In association with the pulmonary calcium-phosphate deposits the P207 content of the lung was also increased whereas in uremic patients without pulmonary calcification lung P207 was within the normal range (Table VI) .
The only nondialyzed uremic patient studied who had pulmonary calcification (Table VI) phorus and in uremic bone 1.2% of the phosphorus was present as P207. Only a limited number of other studies have been carried out to measure P207 content of calcified tissues. Perkins and Walker (7) found that between 0.25 and 0.73% of the phosphorus present in rabbit and rat cortical bone, and Cartier (8) found that 0.68 to 0.79% of the phosphorus present in rat bone was P207. Bisaz et al. (9) reported that 0.69 and 0.13% of the phosphorus in dentin and enamel, respectively, was P207. Thus the P207 content of control human bones in our study is quite similar to that found by other authors in a variety of calcified tissues; but the P207 content of uremic bone is considerably higher. Burton et al. (10) found that P207 was rapidly adsorbed from an incubating media onto the surface of apatite crystals. These authors suggested that a fixed number of binding sites were available for P207 adsorption by the crystal surface. The studies of Krane and Glimcher (11) and Jung et al. (12) show that P207 binding by apatite crystals is not restricted to one class of binding sites. Krane and Glimcher (11) found that apatite crystals when incubated with inorganic pyrophosphate took up P207 rapidly as a result of adsorption on the crystal surface. The P207 adsorbed by the apatite crystal could be hydrolyzed by pyrophosphatase. A second type of binding occurred when the crystals were exposed to ATP. It was suggested that there was a phosphoryl transfer of the terminal phosphoryl of the nucleotide to form P207 (11, 13) . The P207 formed by this reaction appears to be bound to the crystal as a result of a transphosphorylation reaction between the P207 and phosphorus of the apatite crystal (11, 13) . The P207 present in apatite crystals in this form is resistant to pyrophosphatase (11). Two pieces of evidence are presented in this study which would suggest that in uremic patients the excess bone P207, if it is attached to the apatite crystal, is formed in situ and present in the transphosphorylated form. First, the amount of P207 adsorbed from an incubating media by control bones and uremic bones with normal and high P207 levels was similar. It would be expected that if the excess P207 had been present as a result of being adsorbed on the crystal surface that additional P207 adsorption would be decreased because of a reduced number of available binding sites. Secondly the P207 present in all types of bone was resistant to hy- (14) . Although renal osteodystrophy is almost certainly a result of multiple factors, a number of which are known, the present study suggests that P207 may also be involved in the pathogenesis of this condition. The increased bone P207, which is resistant to pyrophosphatase, could have major implications in disturbing normal bone calcification processes. Termine and Posner (15) have suggested that P207 existing in the transphosphorylated form could prevent the conversion of amorphous calcium-phosphate to crystalline apatite. Russell and Avioli (16) have shown that the amount of amorphous calcium-phosphate is increased in the bones of uremic animals. In the present study, percent bone ash was found to be significantly reduced in uremic bones with high P207 content. In addition there was a significant inverse correlation in the high P207 bones between duration of dialysis and percent bone ash.
However, what may be more important than P207 disturbing bone calcification mechanisms is the relationship found between bone P207 content and soft tissue calcification. All dialyzed uremic patients who had a bone P207 level greater than 1.4 mg/g had extensive pulmonary calcification. In addition no uremic patient with normal bone P207 had more than a slight elevation of the pulmonary calcium content. The pulmonary calcium-phosphate deposits in patients with high bone P207 were also high in P207. Low P207 pulmonary calcification was found in one nondialyzed uremic patient who had normal bone P207. The thermochemical properties of this deposit were unlike those found in uremic patients but similar to those described in hypercalcemic patients (3) . This would suggest that either this deposit did not occur as a result of the uremic state or else visceral calcification in nondialyzed uremic patients is different from that found in dialyzed uremic patients.
The present study gives little insight into the mechanism responsible for the disturbed P207 metabolism in dialyzed uremic patients. The fact that P207 may exist in bone in the transphosphorylated form would suggest that nucleotide metabolism might be abnormal in uremic patients. However, since magnesium was found to be significantly higher in uremic patients' bones containing high P207 levels and high magnesium levels have uniformly been found in visceral calcium-phosphate deposits containing P207 (3) a disturbance of magnesium metabolism might be responsible for the excess P207 deposition. It is possible that hypermagnesemia alone could cause the deposition of magnesium P207 in soft tissue and bones. Since magnesium is tightly bound to ATP, it is conceivable that a magnesium ATP salt undergoes a phosphoryl transfer reaction and that both magnesium and P207 are released and subsequently bound to the bone crystal. Thus, disturbances in magnesium and ATP metabolism resulting in increased bone P207 are not mutually exclusive. This explanation would imply an abnormal release of magnesium ATP from cells into the circulation.
